NASDAQ:TCRR
Delisted
TCR2 Therapeutics Inc. Stock News
$1.48
+0 (+0%)
At Close: Aug 30, 2023
TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
06:45am, Thursday, 05'th Aug 2021
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from c
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer
06:45am, Tuesday, 20'th Jul 2021
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with soli
TCR2 Therapeutics - Promising Technology And Upside Potential
04:11pm, Tuesday, 15'th Jun 2021
TCRR is developing an exciting new TCR-T cell-based therapy that has the potential to deliver improved therapeutic outcomes when compared to CAR-T cell-based therapies.
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
06:45am, Wednesday, 26'th May 2021
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
06:45am, Thursday, 13'th May 2021
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca
TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
06:45am, Thursday, 29'th Apr 2021
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
08:31am, Saturday, 10'th Apr 2021
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from
TCR² Therapeutics to Present at the Needham Healthcare Conference
06:45am, Thursday, 08'th Apr 2021
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
06:45am, Thursday, 11'th Mar 2021
- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
04:45pm, Wednesday, 10'th Mar 2021
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
10:03pm, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell ther
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
06:24am, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell ther
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
08:00am, Friday, 08'th Jan 2021
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21
- TC-210 induced tumor regression in all of the first eight patients
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
04:05pm, Friday, 11'th Dec 2020
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients sufferi
